Jazz Pharmaceuticals
JAZZ
319 hedge funds and large institutions have $8.31B invested in Jazz Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 114 increasing their positions, 103 reducing their positions, and 37 closing their positions.
41% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 37
17% more call options, than puts
Call options by funds: $80.3M | Put options by funds: $68.4M
11% more repeat investments, than reductions
Existing positions increased: 114 | Existing positions reduced: 103
9% more capital invested
Capital invested by funds: $7.59B → $8.31B (+$720M)
4% more funds holding
Funds holding: 306 → 319 (+13)
1.38% more ownership
Funds ownership: 87.52% → 88.9% (+1.4%)
0% more funds holding in top 10
Funds holding in top 10: 11 → 11 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$133M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$130M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
+$122M |
| 4 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$76.1M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$70M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$125M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$98M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$87.9M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$52.6M |
| 5 |
TCP
Tourbillon Capital Partners
New York
|
-$27.9M |
JAZZ Hedge Fund Activity: Q2 2017 in Review
319 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q2 2017, worth a combined $8.31B — up 9.5% from $7.59B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new JAZZ positions and 37 closed out — a net gain of 15 holders — while 114 added to existing stakes and 103 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $133M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $125M sold.
- 319 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q2 2017, up from 306 in Q1 2017.
- Funds reported $8.31B of Jazz Pharmaceuticals stock for Q2 2017, up 9.5% quarter-over-quarter.
- 52 funds opened new Jazz Pharmaceuticals positions in Q2 2017 and 37 closed out, a net change of +15 holders.
- The largest Jazz Pharmaceuticals buyer in Q2 2017 was Janus Henderson Group, an estimated $133M added.
- The largest Jazz Pharmaceuticals seller in Q2 2017 was PFM Health Sciences, an estimated $125M sold.
Based on aggregated 13F filings for Q2 2017.